Tenax Therapeutics sees a surge in shares as US regulators allow its patent application for heart failure therapy, levosimendan, extending IP protection.
On January 22, 2024, Minim, Inc., a Delaware corporation (the "Company"), entered into a Letter Agreement re Product Purchase (the "Letter Agreement") and a Debt Settlement Agreement (the "Settlement Agreement," and with
https://www.rackspace.com/newsroom/rackspace-technology-government-solutions-authorization-aws-federal-environment
Rackspace Technology® (NASDAQ:RXT), a leading end-to-end, multicloud technology